CRISPR-Cas9 technology tagged posts

Researchers solve protein mystery

Figur 1, se bildetekst for mer informasjon
N-terminal acetylation by NatC shields proteins from degradation

Researchers have uncovered that proteins use a common chemical label as a shield to protect them from degradation, which in turn affects motility and aging. Proteins are key to all processes in our cells and understanding their functions and regulation is of major importance.

“For many years, we have known that nearly all human proteins are modified by a specific chemical group, but its functional impact has remained undefined,” says professor Thomas Arnesen at the Department of Biomedicine, University of Bergen.

He explains:

“One of the most common protein modifications in human cells is N-terminal acetylation, which is an addition of a small chemical group (acetyl) at the starting tip (N-terminus) of a protein...

Read More

CRISPR technology to Cure Sickle Cell Disease

Blood smear illustrating sickle cell anemia
This blood smear shows sickle cell disease.

University of Illinois Chicago is one of the U.S. sites participating in clinical trials to cure severe red blood congenital diseases such as sickle cell anemia or Thalassemia by safely modifying the DNA of patients’ blood cells.

The first cases treated with this approach were recently published in an article co-authored by Dr. Damiano Rondelli, the Michael Reese Professor of Hematology at the UIC College of Medicine. The article reports two patients have been cured of beta thalassemia and sickle cell disease after their own genes were edited with CRISPR-Cas9 technology. The two researchers who invented this technology received the Nobel Prize in Chemistry in 2020.

In the paper published in the New England Journal of Medicine, CRISPR-Ca...

Read More